Matthew Barcus
Stock Analyst at Chardan Capital
(3.09)
# 1,088
Out of 4,667 analysts
23
Total ratings
23.81%
Success rate
28.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $14 → $12 | $2.90 | +313.79% | 2 | Nov 8, 2024 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $5.70 | +373.68% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.94 | +643.73% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $26.17 | +22.28% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $2.47 | +8,806.88% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $3.05 | +195.57% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $9.33 | -14.26% | 1 | Mar 17, 2023 | |
| VINC Vincerx Pharma | Maintains: Buy | $4 → $3 | $0.28 | +988.53% | 3 | Nov 17, 2022 |
Zura Bio
Nov 8, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $2.90
Upside: +313.79%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $5.70
Upside: +373.68%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.94
Upside: +643.73%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $26.17
Upside: +22.28%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $2.47
Upside: +8,806.88%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $3.05
Upside: +195.57%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $9.33
Upside: -14.26%
Vincerx Pharma
Nov 17, 2022
Maintains: Buy
Price Target: $4 → $3
Current: $0.28
Upside: +988.53%